Subgroup analyses of OS in all randomized Japanese patients
NIVO
DISEASE, METASTASES
Subgroup analyses were performed for age, sex, ECOG PS, tumor-cell PD-L1 expression status, disease status at study entry, number of organs with metastases, and smoking history using unstratified Cox proportional hazards modeling with treatment as the only covariate (Online Resource 5). OS numerically favored NIVO + IPI or NIVO + Chemo versus Chemo alone across multiple prespecified subgroups in all randomized patients. In both, NIVO + IPI and NIVO + Chemo arms, the OS prolongation effect was numerically larger with the higher tumor-cell PD-L1 expression subgroup, with no further enrichment of efficacy observed in any of the cutoff values higher than 1% (Online Resource 5).